Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Kymera Therapeutics announced Phase 1 results for KT-621, a first-in-class oral STAT6 degrader, in healthy Japanese adults at the Japanese Dermatological Association Annual Meeting. The data showed consistent safety and pharmacokinetic/pharmacodynamic profiles with previous studies, demonstrating rapid and sustained STAT6 degradation (≥98% at Day 7). The company has parallel Phase 2b trials ongoing in atopic dermatitis (BROADEN2) and asthma (BREADTH), with data expected by mid-2027 and late 2027, respectively.

06/12/2026, 7:00 AM • GlobeNewswire

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

Kymera Therapeutics announced preclinical data for KT-579, an oral IRF5 degrader, demonstrating disease-modifying activity in lupus models comparable or superior to approved therapies. The compound showed consistent activity across multiple disease pathways including Type I interferons and pro-inflammatory cytokines. Phase 1 healthy volunteer trial is ongoing with data expected in the second half of 2026, followed by a planned patient proof-of-concept trial in lupus.

06/08/2026, 7:00 AM • GlobeNewswire

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

Kymera Therapeutics announced presentations of Phase 1b clinical data for KT-621, its first-in-class oral STAT6 degrader, at the Society for Investigative Dermatology and American Thoracic Society congresses. The data demonstrated deep STAT6 degradation in blood and skin, reductions in Type 2 inflammatory biomarkers, and favorable safety profile. Parallel Phase 2b trials in atopic dermatitis and asthma are ongoing with data expected by mid-2027 and late 2027, respectively.

05/15/2026, 7:00 AM • GlobeNewswire

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

Kymera Therapeutics announced participation in upcoming investor conferences in May 2026 and presented preclinical data for KT-579, its first-in-class oral IRF5 degrader for inflammatory bowel disease, showing activity comparable or superior to approved therapies. The company has Phase 1 data expected in H2 2026 and ongoing Phase 2b trials for KT-621 with results anticipated by mid-to-late 2027.

05/06/2026, 7:00 AM • GlobeNewswire

Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026

Kymera Therapeutics will report Q1 2026 financial results on April 30, 2026. The company announced FDA Fast Track designation for KT-621, a first-in-class oral STAT6 degrader for moderate to severe asthma, with Phase 2b trial data expected in late 2027. Additionally, Gilead Sciences exercised its option to license KT-200, triggering a $45 million milestone payment to Kymera.

04/23/2026, 7:00 AM • GlobeNewswire

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit

Hedge fund BVF fully exited its position in Protagonist Therapeutics (PTGX), selling 2.56 million shares worth $170.12 million. Despite the stock rallying 120% over the past year, the fund's exit reflects a disciplined capital rotation strategy following the company's New Drug Application submission for rusfertide in polycythemia vera, marking a shift from clinical-stage risk to regulatory execution risk.

02/25/2026, 3:28 PM • The Motley Fool

Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction

Hedge fund BVF invested $52 million in Disc Medicine (IRON) by acquiring 650,000 shares in Q4, demonstrating conviction in the clinical-stage biotech company despite recent FDA setbacks. The investment was made before the FDA's Complete Response Letter in February and a subsequent 20% stock decline. With $791 million in cash runway through 2029, Disc Medicine's investment thesis now hinges on Phase 3 APOLLO trial data expected in Q4 and a potential FDA decision by mid-2027.

02/25/2026, 3:19 PM • The Motley Fool

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Kymera Therapeutics announced its 2026 clinical and preclinical milestones, including ongoing Phase 2b trials for KT-621 in atopic dermatitis and asthma with data expected in 2027, initiation of Phase 1 testing for KT-579 in Q1 2026, and advancement of at least one new development candidate toward IND. The company maintains $1.6 billion in cash with runway into 2029.

01/13/2026, 7:00 AM • GlobeNewswire

Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks

Three stocks have attracted over $100 million in insider buying from prominent institutional investors: DoorDash (Sequoia Capital), Kenvue (Starboard Value LP), and Kymera Therapeutics (Baker Bros. Advisors). While these purchases signal confidence from sophisticated capital, investors should consider offsetting insider sales and the long-term viability of these bets.

01/02/2026, 12:30 PM • Investing

Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering

Kymera Therapeutics plans to raise $602 million through a public offering of 7 million common stock shares at $86 per share, with proceeds intended to advance its preclinical and clinical degrader programs.

12/09/2025, 11:30 PM • GlobeNewswire

Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Kymera Therapeutics initiated dosing in its BROADEN2 Phase 2b clinical trial for KT-621, an oral STAT6 degrader targeting moderate to severe atopic dermatitis. The company expects to report trial data by mid-2027 and is also preparing for a Phase 2b asthma trial in early 2026.

11/25/2025, 7:00 AM • GlobeNewswire

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

Kymera Therapeutics will report Q3 2025 financial results on November 4, 2025, and has recently presented preclinical data for two novel oral protein degrader drug candidates targeting immunological diseases.

10/28/2025, 7:00 AM • GlobeNewswire

Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses

Kymera Therapeutics presented positive Phase 1 trial results for KT-621, an oral STAT6 degrader targeting immunological diseases like atopic dermatitis and asthma, demonstrating robust target engagement and potential as an alternative to existing biologics.

09/17/2025, 7:00 AM • GlobeNewswire

Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

Kymera Therapeutics announced the appointment of Brian Adams as Chief Legal Officer, succeeding Ellen Chiniara who is retiring. Adams brings nearly two decades of legal leadership experience in life sciences and will oversee legal, governance, and intellectual property functions.

09/03/2025, 7:00 AM • GlobeNewswire

Hatteras Venture Partners Raises Over $200 Million in Capital Across Two Healthcare-Focused Funds

Hatteras Venture Partners closed two funds totaling over $200 million and celebrated investing in its 100th portfolio company, marking 25 years of supporting healthcare innovation with successful investments in transformative life sciences companies.

08/13/2025, 8:00 AM • GlobeNewswire